AF
KROS icon

Amalgamated Financial’s Keros Therapeutics KROS Stock Holding History

Amalgamated Financial’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$138K Buy
+2,542
New +$130K ﹤0.01% 2034

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Amalgamated Financial's KROS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Keros Therapeutics (KROS) in Q1 2022: 2,542 shares worth $138K. The stake represents ﹤0.01% of the portfolio and ranks #2034 among its holdings.

106 funds tracked by Wall St. Rank hold KROS as of Q1 2022.

  • Amalgamated Financial held 2,542 shares of Keros Therapeutics worth $138K as of Q1 2022.
  • Keros Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Keros Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2034 holding.
  • 106 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.